Is it okay to take NMN every day？

In recent years, nicotinamide mononucleotide (NMN), a highly anticipated "star molecule" in the anti-ageing field, has transitioned from cutting-edge laboratories to the mass consumer market, becoming one of the most talked-about topics in the plant extract and dietary supplement industries. With increasing awareness of consumer health, more people are considering using NMN as a daily supplement.

To answer 'whether it can be taken daily', safety considerations come first. Fortunately, by the end of 2025, the scientific community will have accumulated a large amount of safety data on NMN in short-term human applications.

Since 2023, multiple high-quality human clinical trials, including randomised, double-blind, placebo-controlled studies, have consistently concluded that daily use of NMN within the recommended dosage range is safe for healthy adults. For example, according to a multicenter, randomised, double-blind clinical trial published in the authoritative journal Geroscience in 2023, healthy middle-aged adults were supplemented with 300mg, 600mg, and 900mg of NMN daily. During the 60-day study, all dose groups showed good safety and tolerability. In addition, multiple other studies have tested doses ranging from 250mg to 1250mg daily for weeks to months, and no significant physiological adverse reactions or serious side effects have been reported.

These studies have confirmed through rigorous monitoring of electrocardiogram, blood pressure, blood biochemical indicators, and organ function that NMN does not cause a significant burden on key organs such as the heart, liver, and kidneys.

The confidence in the safety of NMN also comes from an understanding of its metabolic pathways in the body. Research has shown that oral NMN can be rapidly absorbed by the body and converted into the key coenzyme NAD+. Its metabolites are mainly excreted through urine and faeces, and there is no evidence to suggest that it will accumulate harmful substances in internal organs. This clear metabolic pathway provides important safety theoretical support for the long-term daily use of NMN.

Although the existing evidence is encouraging, as rigorous researchers, we must acknowledge the limitations of current research. At present, the vast majority of human clinical trials are concentrated within 6 months, and there is still a scarcity of long-term, large-scale clinical data on the daily use of NMN for several consecutive years. Although a one-year mouse study did not find any significant toxic side effects
But this cannot be completely equated with the long-term safety of the human body. Therefore, the scientific community generally believes that longer cycles of clinical observation are still needed in the future to construct a complete long-term safety profile.

For practitioners in the plant extract industry, understanding the production standards and global regulations of NMN is crucial. In 2025, the global NMN regulatory landscape will have undergone profound changes, bringing new opportunities and challenges to the market.

1. Production quality is the lifeline of safety and effectiveness

High-quality NMN products must meet strict quality standards. The consensus within the industry is that NMN raw materials produced using green enzymatic technology should be given priority, as this process can maximise the biological activity of molecules and avoid harmful chemical residues that may arise from chemical synthesis methods. In addition, GMP (Good Manufacturing Practice) certification is the fundamental threshold for ensuring the standardisation of the production process. High purity (such as ≥ 99.5%) and authoritative third-party laboratory testing reports are key indicators for judging product quality. Some leading brands even follow stricter French American dual certification or the EU's OULF safety standard system, providing consumers with a higher level of protection.

• The United States: 2025 is a milestone year for the NMN market in the United States. The US Food and Drug Administration (FDA) officially issued a clarification on September 29, 2025, confirming that NMN is not excluded from the definition of dietary supplements, essentially restoring its legal sales status as a dietary supplement in the United States. This decision has put an end to the controversy and uncertainty surrounding the legal status of NMN since 2022, injecting strong confidence into the market.
• Australia: The Australian Medicines Agency (TGA) has included NMN in the list of permitted ingredients for "listed drugs (AUST L)" by 2025. This means that NMN products that meet TGA composition standards and quality requirements can be sold in the Australian market through compliance pathways, marking a clarification of their regulatory status.
• China: The National Health Commission of China restarted the acceptance and technical review of NMN as a new food additive variety in January 2025. This measure is seen as a crucial step for China to include NMN in the formal food ingredient regulatory system, indicating that the compliance process in the domestic market is accelerating.
• EU and Japan: The approval process for the EU's NMN "Novel Food" is underway, and some companies have entered the safety assessment stage of the European Food Safety Authority (EFSA). Japan, on the other hand, has already listed NMN as a legal food ingredient and has a relatively mature regulatory framework.

Based on the latest scientific evidence and regulatory developments in 2025, can we discuss whether taking NMN daily is acceptable? "This question provides a cautious yet optimistic answer:

Yes, for healthy adults, according to the current large number of short - to medium-term clinical trial results, taking high-quality NMN products at the recommended daily dose of 250mg-900mg is considered safe and can bring verifiable health benefits.

However, we must recognise that the scientific puzzle about its long-term (over several years) safety still needs time to be completed.

For more details about NMN, connect with Serrisha from APPCHEM. (Email: cwj@appchem.cn; +86-138-0919-0407)

Reference

[1]Shintaro Yamaguchi, J. Irie et al. "Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men." Endocrine journal (2024).
[2]Bin Yu, Xiaotong Jing et al. "The versatile multi-functional substance NMN: its unique characteristics, metabolic properties, pharmacodynamic effects, clinical trials, and diverse applications." Frontiers in Pharmacology (2024).
[3]Ryota Nakajima, Hidekazu Watanabe et al. "Placebo-controlled randomised double-blind parallel-group trial of the safety of overdose intake of nicotinamide mononucleotide." Fundamental Toxicological Sciences (2025).
[4]Keisuke Okabe, Keisuke Yaku et al. "Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects." Frontiers in Nutrition (2022).
[5]Yuichiro Fukamizu, Y. Uchida et al. "Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women." Scientific Reports (2022).